

New prescription drug report

To: The Office of the Attorney General of Vermont

On April.12 2023, Epic Pharma, LLC (Epic Pharma) introduced "High Cost" Prescription Drugs whose Wholesale Acquisition Cost exceeds threshold set for a specialty drug under the Medicare Part D program(\$830):

NDC11	NDC Description	Trade or Generic	Manufacturer	Date Introduced	WAC
42806037130	Deferasirox 90mg Oral Granules 30 sachets	G	Epic Pharma, LLC	4/12/2023	\$ 1,025.01
42806037230	Deferasirox 180mg Oral Granules 30 sachets	G	Epic Pharma, LLC	4/12/2023	\$ 2,049.98
42806037330	Deferasirox 360mg Oral Granules 30 sachets	G	Epic Pharma, LLC	4/12/2023	\$ 4,099.87

(1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally:

Because this information is not in the public domain or publicly available and is confidential, Epic Pharma limits its response to this item.

(2) the estimated volume of patients who may be prescribed the drug:

The estimated average number of patients per month is unknown to Epic Pharma LLC.

(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval: NO

(4) the date and price of acquisition if the drug was not developed by the manufacturer

Epic Pharma developed the product.

Sincerely,

Epic Pharma LLC